In this study, we aimed to analyze the association of clinical factors and genetic factors, including ALK fusion variants and BIM polymorphism, with crizotinib PFS and overall survival (OS) in advanced EML4–ALK(+) NSCLC patients. The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.